BIOTECH: A Road Toward Value-Based Pricing
October 25th, 2006
 by
Leighton Read
|
In his post, Jamie Robinson has raised the specter of an upside-down world of setting prices for biomedical innovations based on cost. Before we examine his serious admonition to focus on value in pricing new biotechnology drugs, let’s walk down the other trail: the argument that drugs should be pricy because they cost so darn... Read the rest of this entry »
